Buprenorphin/Naloxon "G.L. Pharma" 2+0,5 mg resoribletter, sublinguale デンマーク - デンマーク語 - Lægemiddelstyrelsen (Danish Medicines Agency)

buprenorphin/naloxon "g.l. pharma" 2+0,5 mg resoribletter, sublinguale

g.l. pharma gmbh - buprenorphinhydrochlorid, naloxonhydrochloriddihydrat - resoribletter, sublinguale - 2+0,5 mg

Buprenorphin/Naloxon "G.L. Pharma" 8+2 mg resoribletter, sublinguale デンマーク - デンマーク語 - Lægemiddelstyrelsen (Danish Medicines Agency)

buprenorphin/naloxon "g.l. pharma" 8+2 mg resoribletter, sublinguale

g.l. pharma gmbh - buprenorphinhydrochlorid, naloxonhydrochloriddihydrat - resoribletter, sublinguale - 8+2 mg

Dasatinib Accordpharma 欧州連合 - デンマーク語 - EMA (European Medicines Agency)

dasatinib accordpharma

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiske midler - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Lamivudine Teva Pharma B.V. 欧州連合 - デンマーク語 - EMA (European Medicines Agency)

lamivudine teva pharma b.v.

teva b.v.  - lamivudin - hiv infektioner - antivirale midler til systemisk anvendelse - lamivudin teva pharma b. indikeres som en del af antiretroviral kombinationsbehandling til behandling af humane immunsvigt-virus (hiv) -inficerede voksne og børn.